Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07067255 | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer(BAH2573-104) | recruiting | Phase 1 / Phase 2 | 80 | Essen BiotechOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07067307 | Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07068906 | A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07069335 | A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer | recruiting | Phase 1 | 24 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07066995 | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer(BAH2573-102) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03971799 | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07063407 | Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 1 | 50 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04592211 | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer | recruiting | Phase 1 / Phase 2 | 71 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05894824 | T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 58 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06873763 | Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 52 | STCube, Inc.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07059832 | Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors | active not recruiting | Phase 1 / Phase 2 | 30 | First Hospital of China Medical UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04891757 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 144 | Foghorn Therapeutics Inc.INDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05195619 | Personalized DC Vaccines in Non Small Cell Lung Cancer | active not recruiting | Phase 1 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT07058116 | Accelerator-based BNCT (Boron Neutron Capture Therapy) for Head and Neck Carcinoma.(BNCT) | recruiting | Phase 1 | 10 | Neutron Therapeutics, LLCINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06232083 | A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR) | recruiting | Phase 1 | 20 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06773481 | BC008-1A Injection for Recurrent CNS WHO G4 Glioma | recruiting | Phase 1 | 40 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06773507 | Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07057349 | CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer | not yet recruiting | Phase 1 | 40 | Cytosite Biopharma Inc.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06112808 | A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | active not recruiting | Phase 1 | 300 | BiocadINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06385522 | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | not yet recruiting | Phase 1 | 37 | Boston Immune Technologies and TherapeuticsINDUSTRY | 0 | Jul 8, 2025 | clinicaltrials |
| NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma(DBPilot) | recruiting | Phase 1 | 38 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06980454 | Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics | active not recruiting | Phase 1 | 322 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07053488 | CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection | recruiting | Phase 1 / Phase 2 | 90 | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05607953 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 60 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05797805 | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Iterion TherapeuticsINDUSTRY | 2 | Jul 4, 2025 | clinicaltrials |
| NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 110 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06630624 | Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM(INJECTABL-II) | recruiting | Phase 1 / Phase 2 | 120 | M.R. MeijerinkOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT04740424 | FS222 First in Human Study in Patients With Advanced Malignancies | recruiting | Phase 1 | 260 | invoX Pharma LimitedINDUSTRY | 7 | Jul 1, 2025 | clinicaltrials |
| NCT06787144 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants(CML) | recruiting | Phase 1 | 21 | Enliven TherapeuticsINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06946927 | A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation | recruiting | Phase 1 | 72 | JemincareINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07045454 | A Study of MHB118C Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04047706 | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07043218 | A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 | 36 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04648202 | FS120 Phase 1/1b Study in Patients With Advanced Malignancies | active not recruiting | Phase 1 | 82 | invoX Pharma LimitedINDUSTRY | 2 | Jun 27, 2025 | clinicaltrials |
| NCT06240728 | A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 | recruiting | Phase 1 | 144 | NextPoint Therapeutics, Inc.INDUSTRY | 2 | Jun 27, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07040436 | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1(REVERT) | not yet recruiting | Phase 1 / Phase 2 | 41 | Oncodesign Precision MedicineINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT06896110 | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | enrolling by invitation | Phase 1 | 34 | Andrew P. GrovesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07034053 | Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 50 | Ekaterina LaukhtinaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04121455 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients(GLORIA) | active not recruiting | Phase 1 / Phase 2 | 117 | TME Pharma AGINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | recruiting | Phase 1 | 66 | Orbus Therapeutics, Inc.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07009002 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 16, 2025source: clinicaltrials